Compositions of protein receptor tyrosine kinase inhibitors

a technology of tyrosine kinase inhibitors and protein receptors, which is applied in the field of synthetic substituted heterocyclic compounds, can solve the problems of few trka inhibitors, high trka kinase selectivity,

Active Publication Date: 2014-08-14
PURDUE PHARMA LP
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021]In another aspect, the present invention provides pharmaceutical compositions comprising one or more compounds as described above or a salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable vehicle.
[0022]In still another aspect, the present invention provides methods for selectively inhibiting or antagonizing NGF receptor TrkA for treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination, with therapeutic effective amount of the compound as

Problems solved by technology

Besides antibodies, however, few TrkA inhibitors are known and very few (if any) s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions of protein receptor tyrosine kinase inhibitors
  • Compositions of protein receptor tyrosine kinase inhibitors
  • Compositions of protein receptor tyrosine kinase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024]The present invention relates to novel synthetic small molecules that act as inhibitors and / or antagonists of the members of Trk family protein kinases, in particularly the NGF receptor. TrkA.

5.1 Definitions

[0025]Terms used in the claims and specification are defined as set forth below unless otherwise specified.

[0026]The term “a compound of the present invention”, “the compound of the present invention”, “compounds of the present invention”, or “the present compounds” refers to one or more compounds encompassed by the structural formulae and / or any subgeneric formulae disclosed herein and includes any specific compounds within these generic formula whose structure is disclosed herein. Compounds of the invention may contain one or more chiral centers and / or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), the racemic mixtures, enantiomers or diastereomers. Accordingly, the chemical structures depicted herein encompa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Percent by massaaaaaaaaaa
Body weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a Divisional application of U.S. patent application Ser. No. 13 / 133,565, filed Jun. 8, 2011, which is a National Stage Application of International Application No. PCT / US2009 / 067197, filed on Dec. 8, 2009, which claims priority to U.S. Provisional Application No. 61 / 120,827, filed on Dec. 8, 2008, the entire contents of each of which are herein incorporated by reference in their entirety for all purposes.1. FIELD OF THE INVENTION[0002]The present invention relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and / or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorde...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D261/20A61K31/496A61K45/06
CPCC07D215/20C07D221/06C07D223/32C07D241/44C07D261/20C07D265/36C07D279/16C07D295/13C07D307/77C07D403/14C07D413/12C07D417/12C07D471/04C07D487/04C07D491/04C07D493/06C07D495/04C07D498/04C07D498/06C07D513/04A61K31/496A61K45/06A61K31/404A61K31/4355A61K31/4545A61K31/4709A61K31/495A61K31/498A61K31/4985A61K31/519A61K31/5377A61K31/538A61K31/5383A61K31/5415A61K31/542A61K31/55A61K31/551A61K31/5513A61K31/554C07D215/227C07D221/12C07D221/16C07D223/14C07D223/16C07D281/10C07D403/12C07D491/048A61K31/497A61P1/04A61P3/10A61P7/02A61P9/00A61P9/10A61P11/00A61P13/02A61P13/10A61P17/00A61P17/02A61P17/06A61P19/02A61P21/00A61P21/02A61P23/00A61P25/00A61P25/02A61P25/04A61P25/08A61P25/22A61P25/24A61P25/30A61P25/32A61P25/34A61P29/00A61P31/00A61P31/12A61P31/18A61P35/00A61P35/02A61P35/04A61P37/02A61P37/06A61P39/02A61P43/00C07D407/12C07D413/10C07D207/09
Inventor WU, JAY JIE-QIANGWANG, LING
Owner PURDUE PHARMA LP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap